

PHARMACEUTICAL 2023











PHARMACEUTICAL 2023

Zomedica Corp. Rank 5 of 446



The relative strengths and weaknesses of Zomedica Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zomedica Corp. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 60% points. The greatest weakness of Zomedica Corp. is the variable Other Revenues, reducing the Economic Capital Ratio by 2.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 303%, being 260% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	123,501
Cost of Goods Sold	5,278
Intangible Assets	105,778
Liabilities, Current	7,811
Liabilities, Non-Current	3,162
Other Assets	43,522
Other Compr. Net Income	-845
Other Expenses	-2,365
Other Liabilities	1,245
Other Net Income	2,543
Other Revenues	18,930
Property and Equipment	6,809
Research and Development	2,578
Selling, General and Administrative Expense	32,997

Output Variable	Value in 1000 USD
Assets	279,610
Liabilities	12,218
Expenses	38,488
Revenues	18,930
Stockholders Equity	267,392
Net Income	-17,015
Comprehensive Net Income	-17,438
Economic Capital Ratio	303%

